Investor Relations Corporate Profile Assembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Data Provided by Refinitiv. Minimum 15 minutes delayed. Press Releases See all news Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights Assembly Biosciences Announces Effective Date of Reverse Stock Split Assembly Biosciences Provides Anticipated Development Milestones for 2024 Events & Presentations See all upcoming events Nov 10 - Nov 14, 2023 AASLD – The Liver Meeting® 2023 Oct 17, 2023 at 8:30 AM EDT Assembly Bio Webcast: Partnership with Gilead to Develop Next-Generation Antiviral Therapeutics Sep 19 - Sep 23, 2023 2023 International HBV Meeting Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Investor Relations Corporate Profile Assembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Data Provided by Refinitiv. Minimum 15 minutes delayed. Press Releases See all news Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights Assembly Biosciences Announces Effective Date of Reverse Stock Split Assembly Biosciences Provides Anticipated Development Milestones for 2024 Events & Presentations See all upcoming events Nov 10 - Nov 14, 2023 AASLD – The Liver Meeting® 2023 Oct 17, 2023 at 8:30 AM EDT Assembly Bio Webcast: Partnership with Gilead to Develop Next-Generation Antiviral Therapeutics Sep 19 - Sep 23, 2023 2023 International HBV Meeting
